Brain cancer vaccine trial aims to boost Chemo's punch
NCT ID NCT07365280
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests a personalized dendritic cell vaccine (ZSNeo-DC1.1) combined with standard chemotherapy (temozolomide) in 78 adults with newly diagnosed glioblastoma. Participants receive the vaccine as shots during chemo after surgery and radiation. The goal is to see if the combo improves how long the cancer stays under control compared to chemo alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- personalized dendritic cell vaccine (ZSNeo-DC1.1) plus temozolomide chemotherapy
- What this could lead to
- If it works, this could offer a new way to extend survival for people with glioblastoma, a tough-to-treat brain cancer.
- What could go wrong
- This is a small, early-phase trial (78 people) with no results yet. The vaccine is personalized, which is complex, and it may not improve outcomes or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a One-Two punch slow recurrent brain cancer?